Obesity Modifies the Performance of Fibrosis Biomarkers in Nonalcoholic Fatty Liver Disease.
Sami QadriNoora AhlholmIda LønsmannPaola PellegriniAnni PoikolaPanu K LuukkonenKimmo PorthanAnne JuutiHenna SammalkorpiAnne K PenttiläRoberta D'AmbrosioGiorgio SoardoDiana Julie LeemingMorten Asser KarsdalJohanna ArolaStergios KechagiasSerena PelusiMattias EkstedtLuca Vittorio ValentiHannes HagströmHannele Yki-JärvinenPublished in: The Journal of clinical endocrinology and metabolism (2022)
In obese patients, the best-performing fibrosis biomarkers are ADAPT and the inexpensive FIB-4, which are unaffected by BMI. The widely used NFS loses specificity in obese individuals, which may be corrected with BMI-adjusted cutoffs.